^
Association details:
| Biomarker: | MET amplification + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) + Tabrecta (capmatinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
Published date:
03/10/2022
Excerpt:
...data from another combination (capmatinib 400 mg plus gefitinib 250 mg) in a phase Ib/II trial in patients with MET-amplified and EGFR-mutated NSCLC for whom EGFR inhibitor therapy had failed (n = 100). The phase II results showed an ORR of 29% and PFS of 5.5 months with the capmatinib plus gefitinib combination. A subgroup analysis based on MET gene copy number (GCN) and IHC categories revealed that patients with GCN ≥ 6 and IHC 3+ had better ORRs (47 and 32%, respectively) (Table 3).
DOI:
10.1007/s40291-021-00568-w
